- Home
- MSB vs CLLS Comparison
MSB vs CLLS Comparison
Compare MSB & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSB
- CLLS
- Stock Information
- Founded
- MSB 1961
- CLLS 1999
- Country
- MSB United States
- CLLS France
- Employees
- MSB N/A
- CLLS N/A
- Industry
- MSB Metal Mining
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- MSB Basic Materials
- CLLS Health Care
- Exchange
- MSB Nasdaq
- CLLS Nasdaq
- Market Cap
- MSB 320.9M
- CLLS 299.0M
- IPO Year
- MSB N/A
- CLLS 2007
- Fundamental
- Price
- MSB $30.88
- CLLS $4.16
- Analyst Decision
- MSB
- CLLS Buy
- Analyst Count
- MSB 0
- CLLS 1
- Target Price
- MSB N/A
- CLLS $4.00
- AVG Volume (30 Days)
- MSB 47.6K
- CLLS 168.4K
- Earning Date
- MSB 01-01-0001
- CLLS 11-03-2025
- Dividend Yield
- MSB 22.17%
- CLLS N/A
- EPS Growth
- MSB 425.34
- CLLS N/A
- EPS
- MSB 7.07
- CLLS N/A
- Revenue
- MSB $25,011,439.00
- CLLS $63,438,000.00
- Revenue This Year
- MSB N/A
- CLLS N/A
- Revenue Next Year
- MSB N/A
- CLLS $66.76
- P/E Ratio
- MSB $4.39
- CLLS N/A
- Revenue Growth
- MSB 4.81
- CLLS 223.09
- 52 Week Low
- MSB $22.24
- CLLS $1.10
- 52 Week High
- MSB $37.00
- CLLS $4.59
- Technical
- Relative Strength Index (RSI)
- MSB 47.99
- CLLS 67.60
- Support Level
- MSB $30.12
- CLLS $3.84
- Resistance Level
- MSB $32.00
- CLLS $4.59
- Average True Range (ATR)
- MSB 1.21
- CLLS 0.28
- MACD
- MSB -0.01
- CLLS 0.08
- Stochastic Oscillator
- MSB 59.82
- CLLS 77.18
About MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.